Scotland says yes to BI/Lilly's Tradjenta and Lilly's Bydureon
This article was originally published in Scrip
Executive Summary
Scotland's health technology appraisal body, the Scottish Medicines Consortium (SMC) has said a partial yes to two anti-diabetics drugs, Boehringer Ingelheim/Lilly's DPP-4 inhibitor Tradjenta (linagliptin) and Lilly's GLP1-agonist Bydureon (prolonged-release exenatide). Meanwhile it has given Roche's anticancer Tarceva (erlotinob) a full green light for some lung cancer patients.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.